CLINICAL_TRIALS
trial_result
· 2021-12-03
Clinical Trial Update: Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease [Phase 2]
Summary
Phase 2 dose-ranging study of BMS-945429 in moderate to severe Crohn's disease was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: CSL Behring | Conditions: Crohn's Disease | Phase 2 | Status: TERMINATED | Results posted: 2021-12-03